Vitrakvi (Larotrectinib)

Save over 60% on Vitrakvi from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer in Europe Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany

Information about Vitrakvi (Larotrectinib)

Vitrakvi (Larotrectinib) is a targeted therapy used to treat cancers that are caused by mutations in the NTRK genes. This medication is specifically designed to target and inhibit the action of the tropomyosin receptor kinase (TRK) proteins, which are abnormal due to genetic mutations and contribute to the growth of certain types of cancer. Vitrakvi is a treatment for various types of cancer that have an NTRK gene fusion, regardless of the cancer's location in the body.

Product Highlights

• This includes cancers of various origins (e.g., sarcoma, lung cancer, thyroid cancer, and more) that harbor NTRK gene fusions. These are rare but aggressive mutations in the genes responsible for producing TRK proteins, which can drive cancer growth.
• Vitrakvi is approved for both adult and pediatric patients who have solid tumors with an NTRK gene fusion and do not have other effective treatment options.

Key Ingredient

• Larotrectinib

Key Benefits

• Vitrakvi specifically targets cancers with NTRK gene fusions, providing a treatment option for rare, genetically-driven tumors.
• It can be used to treat multiple types of solid tumors, including those in the brain, lung, and soft tissues.
• Studies have shown that Vitrakvi can lead to significant shrinkage of tumors in patients with NTRK gene fusions, providing a meaningful response when other treatments have failed.
• Many patients tolerate Vitrakvi well, with a relatively manageable side effect profile compared to traditional chemotherapy.
• Vitrakvi is effective regardless of the location of the cancer as long as the tumor has the NTRK gene fusion.

Direction of Use

• The recommended dose of Vitrakvi is 100 mg taken orally twice daily for adults, and for pediatric patients, the dose is based on body weight.
• Vitrakvi can be taken with or without food. It is available in both oral capsules and an oral solution for pediatric patients or those who cannot swallow capsules.
• For maximum efficacy, it is important to take Vitrakvi consistently at the same times each day.
• Treatment with Vitrakvi typically continues until there is evidence of disease progression or unacceptable side effects.

Recommended Dosage Modifications for VITRAKVI for Adverse Reactions

Safety Concerns

• Larotrectinib can cause liver enzyme elevations. Patients should be monitored for liver function regularly during treatment.
• Central nervous system (CNS) side effects, such as dizziness, confusion, and headache, can occur and should be monitored.
• Vitrakvi may cause an increase in the QT interval (a measure of heart rhythm), which can lead to serious heart arrhythmias. Patients should be monitored for heart problems, especially those with pre-existing conditions.
• Fatigue is a common side effect and can impact a patient's ability to carry out daily activities.
• Gastrointestinal issues like nausea and vomiting may occur, especially early in treatment.
• As with many cancer therapies, there is a potential for the development of secondary cancers. Close monitoring is required.

Avoid Vitrakvi (Larotrectinib) If

• If you have had an allergic reaction to Larotrectinib or any of the ingredients in Vitrakvi, it should be avoided.
• Patients with severe liver problems should not use Vitrakvi due to the potential for exacerbating liver toxicity.
• Vitrakvi may harm an unborn baby and is not recommended during pregnancy unless the potential benefit outweighs the risk. It is also not recommended during breastfeeding due to the potential for harm to a nursing infant.
• Vitrakvi should be used cautiously or avoided if taken with certain other medications that can affect liver enzymes or the heart’s QT interval.